BCL2 and B-cell chronic lymphocytic leukemia: Venetoclax, a first-in-class BH3 mimetic agent inhibiting the pro-survival Bcl2 is approved in both front-line and relapsed CLL, delivering remarkable results with complete response rates of up to 30–50% [5,6,7,8].